Progress of Targeted Therapy for Anaplastic Thyroid Cancer

Anaplastic thyroid cancer, an extremely rare malignant tumor of the thyroid gland, is a major cause of mortality in thyroid cancer because of its aggressiveness and poor prognosis. Anaplastic thyroid cancer is typically challenging to treat surgically, and the efficacy of traditional radiotherapy and chemotherapy remains unclear. Meanwhile, the emergence of targeted therapy has radically transformed the traditional mode of tumor treatment. Anti-tumor effects can be achieved by specifically targeting tumor-associated molecules and signaling pathways. Compared with conventional chemotherapy, targeted therapy is able to more precisely target tumor cells while minimizing damage to normal cells. With the advancement of clinical trials on targeted therapy, the use of targeted drugs has been observed to significantly improve overall survival of patients with anaplastic thyroid cancer. Targeted therapy and tumor-related signaling pathways have emerged as research hotspots in the treatment of anaplastic thyroid cancer. This article offers an overview of the progress of targeted therapy for anaplastic thyroid cancer, incorporating current research on targeted drugs in the treatment of this condition.